Purple Biotech Reports Q3 Net Loss of $1.3 Million

Purple Biotech Ltd. reported a net loss of $1.3 million, or $0.29 per basic and diluted ADS, for the three months ended September 30, 2025, compared to a net loss of $0.7 million, or $0.39 per basic and diluted ADS, in the same period of 2024. Finance income, net, was $0.1 million, down from $1.5 million in 2024, mainly due to a lower non-cash gain from the revaluation of outstanding warrants and issuance-related expenses. Operating loss was $1.4 million, a decrease of 35.8% from $2.1 million in the prior year period, primarily due to lower CM24 Phase 2 study expenses. Research and development expenses were $0.6 million, down 56.4% from $1.3 million in 2024. General and administrative expenses remained steady at $0.8 million. As of September 30, 2025, cash and cash equivalents and short-term deposits totaled $10.5 million, with a cash runway expected into the first half of 2027. During the period, the company initiated development of a second CAPTN-3 tri-specific antibody targeting TROP2, achieved a manufacturing milestone for IM1240, and received an intention to grant a European patent for NT219 combinations with immunotherapies or MEK inhibitors. The ongoing NT219 Phase 2 study in recurrent and/or metastatic squamous cell carcinoma of the head and neck continues at the University of Colorado Anschutz Medical Campus. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Purple Biotech Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9576044-en) on November 14, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)